Non-Alcoholic Fatty Liver Disease Market Worth US $ 62.06


Non-alcoholic fatty liver disease worldwide and NAFLD Market Forecast 2021-2031: -By cause of disease (hypertension, heart disease, high blood lipids, type 2 diabetes, obesity, other causes of disease) by type of drug (vitamin E and pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc , other type of drug) by Sales channel (hospital pharmacy, online suppliers, retail pharmacy, other sales channel) Plus analysis of major regional / national markets and major market companies. COVID-19 impact recovery analysis (V-shaped recovery, W-shaped recovery, U-shaped recovery, L-shaped recovery)

Download an exclusive sample report @ https://www.visiongain.com/report/nafld-nash-market-2021/#download_sampe_div

Read this report to find out which strategy to follow

Several key manufacturers, including Genfit, Gilead Sciences and others, are focused on developing an effective treatment for non-alcoholic steatohepatitis (NAFLD). For example, the Food & Drug Administration has accepted a new drug application from Intercept Pharmaceuticals for the treatment of liver fibrosis caused by non-alcoholic steatohepatitis (NAFLD). Intercept also announced that obeticholic acid (OCA), under the brand name Ocaliva, has already been approved for the treatment of primary biliary cholangitis / cirrhosis (an autoimmune disease of the liver) and has a PDUFA (Prescription Drug User) date. Fee Act). provided in the report, the tables have been grouped according to the different development strategies of non-alcoholic fatty liver disease and NAFLD proposed by the players. These include:

  • Additive approach.
  • Modulatory approach.
  • Subtractive approach.

The Visiongain analyst states: “The Global Non-Alcoholic Fatty Liver Disease and NAFLD Market is estimated to be worth US $ 17.43 billion in 2021 and is expected to reach a market value of US $ 62.06 billion by 2031. Non-alcoholic fatty liver disease and NAFLD attract both a lot of investment and money. research activities ”.

In addition to venture capital firms like Seventure Partners, Flagship Pioneering, and BioGaia, federal governments are also keenly interested in NAFLD drugs. This study of Non-alcoholic fatty liver disease market in the global context was motivated by a need to understand the dynamics of this emerging market and the opportunities it offers. Players already in this business can also benefit from this report by gaining insight into the future of this market and other key growth areas.

The study of the report aims to explore the market drivers, restraints and also the market opportunities faced by players in Non-alcoholic Fatty Liver Disease and NAFLD products in different geographies. In addition, it identifies trends, gaps and opportunities in each micro-market segment. Finally, this report identifies key stakeholders, product portfolios and recent developments in order to draw a competitive landscape for players in this market.

Are you ready with the strategy to overcome the challenges of the global market?

Most of the drugs in NAFLD are still not past their approval stage. Currently, no drugs are sold for NAFLD disease, although many drugs are found. This slow approval process has hampered the NAFLD market. In addition, drugs are manufactured at high costs for companies, so drugs, once marketed, will be very expensive. It will also challenge the growth of the market.

The major players featured in this report include:

  • Pfizer Inc. (Pfizer)
  • Roche Holding SA (Roche)
  • Takeda Pharmaceutical Company Limited
  • Intercept Pharmaceuticals, Inc.
  • AstraZeneca SA
  • Novartis AG
  • Merck & Co., Inc.
  • AbbVie Inc. (AbbVie)
  • Gilead Sciences, Inc.
  • Genfit Biotechnology
  • Cardax, Inc.
  • Daewoong Co Ltd
  • Madrigal Pharmaceuticals, Inc.,
  • Mirum Pharmaceuticals, Inc.
  • GW Pharmaceuticals plc.

Study this report for answers to the questions below and how to help you stay up to date.
A SWOT analysis and Porter’s five forces of global NAFLD market

Get the detailed table of contents @ https://www.visiongain.com/report/nafld-nash-market-2021/#download_sampe_div

Key questions this report answers:
• What is the current size of the global non-alcoholic fatty liver disease and NAFLD market today? How much will this market be worth from 2021 to 2031?
• What are the major drivers and restraints that will shape the overall non-alcoholic fatty liver disease and NAFLD market over the next ten years?
• What are the major segments of the global non-alcoholic fatty liver disease and NAFLD market?
• How much will each of these segments be worth for the period 2021 to 2031?
• How will the composition of the market change during this period and why?
• What factors will affect this industry and market over the next ten years?
• What are the largest national markets for non-alcoholic fatty liver disease and NAFLD in the world?
• What is their current status and how will they evolve over the next ten years?
• What are their income potentials until 2031?
• How will political and regulatory forces influence regional markets?
• How will the market shares of the main national markets evolve between now and 2031, and which geographic area will dominate the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are the main non-alcoholic fatty liver disease and NAFLD? What are their income and their latest developments?
• What are some of the most important non-alcoholic fatty liver disease and NAFLD currently in development?
• What are the key trends that will affect the global non-alcoholic fatty liver disease and NAFLD market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape this industry over the next ten years?
• How will the global non-alcoholic fatty liver disease and NAFLD market evolve over the forecast period, 2021 to 2031?
• What will be the main commercial drivers of the market from 2021 to 2031?
• How will the market shares of major national markets change from 2021, and which countries will dominate the market in 2031, achieving the highest incomes and fastest growing?
• How will this industry develop between 2021 and 2031, particularly in R&D?

Find quantitative and qualitative analyzes with independent predictions. Receive information that only our report contains, stay informed with this valuable business intelligence.

Find more research reports on the Therapeutic drug industry, please click on the following links:

Do you have custom requirements that we can help you with? Do you need specific information about a specific country, geographic region, market segment or company? Contact us today, we can discuss your needs and see how we can help you: [email protected]

About Visiongain
Visiongain is one of the fastest growing and most innovative independent market information, the company publishes hundreds of market research reports which she adds each year to her vast portfolio. These reports provide in-depth analysis of 18 industries around the world. The reports cover a 10-year forecast, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works in a range of vertical markets, which can currently influence each other, these markets include the automotive, aviation, chemicals, cybersecurity, defense, energy, food and beverage, materials, packaging, pharmacy and utilities. Our customized and syndicated market research reports mean you can have tailor-made market information tailored to your business needs.

Contact:
Sara peerun
Commercial director
Visiongain Inc.
Phone : + 44 207 549 9987
United States Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
E-mail: [email protected]
The Web: https://www.visiongain.com/
Follow us: LinkedIn | Twitter

SOURCE Visiongain Limited.


About Rhonda Lee

Check Also

How to cope – Cleveland Clinic

It starts with a beer, a glass of wine or a cocktail. Then there’s another…and …

Leave a Reply

Your email address will not be published.